Fully Synthetic, Nature-Inspired Exosome-Mimetics for Melanoma Therapy
| dc.contributor.author | Arda Ozturk N.Z. | |
| dc.contributor.author | Majchrzak O.B. | |
| dc.contributor.author | Ulivi G. | |
| dc.contributor.author | Kirmizibayrak P.B. | |
| dc.contributor.author | Borchard G. | |
| dc.contributor.author | Patrulea V. | |
| dc.contributor.author | Ozer O. | |
| dc.contributor.author | Ozturk, Nahide Zeren Arda | |
| dc.contributor.author | Borchard, Gerrit | |
| dc.contributor.author | Ozer, Ozgen | |
| dc.contributor.author | Patrulea, Viorica | |
| dc.contributor.author | Majchrzak, Oliwia Barbara | |
| dc.contributor.author | Arda Ozturk, Nahide Zeren | |
| dc.contributor.author | Kirmizibayrak, Petek Ballar | |
| dc.contributor.author | Ulivi, Gianluca | |
| dc.date.accessioned | 2026-03-12T14:36:08Z | |
| dc.date.available | 2026-03-12T14:36:08Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Fully synthetic exosome-mimetics (FSEMs) represent a nature-inspired drug delivery system designed to replicate the key physicochemical and biological properties of natural exosomes, while offering the potential to address limitations in scalability and reproducibility associated with natural exosomes. In this study, we prepared FSEMs at the laboratory scale. We loaded them with (–)-epigallocatechin-3-gallate (EGCG) and microRNA-23a (miR-23a), aiming to co-deliver therapeutic small molecules and nucleic acids for the treatment of melanoma. FSEMs were fabricated using three methods: thin-film hydration, ethanol injection, and microfluidics. They were surface-functionalized with either CD9, a tetraspanin involved in membrane fusion, or TSP-1, an adhesion protein promoting cellular interactions. Through physicochemical characterization via dynamic light scattering, we found that FSEMs were ∼ 100 nm in size, of low polydispersity (∼0.2) and showed a negative zeta potential (∼–55 mV). Both EGCG and miR-23a were efficiently encapsulated. SDS-PAGE analysis confirmed successful protein incorporation and correct positioning. In vitro release studies showed minimal premature leakage, supporting their suitability for cellular uptake-mediated delivery. When tested on melanoma cells (MDA-MB-435) and progenitor human dermal fibroblasts (FE002-SK2), FSEMs selectively killed melanoma cells while sparing fibroblasts. Importantly, EGCG within FSEMs was more effective than the free compound. Compared to conventional DOTAP-based liposomes, FSEMs were more selective and induced less off-target cytotoxicity. This study presents a proof-of-concept for fully synthetic, protein-functionalized FSEMs as dual carriers for both chemical and gene-based agents, offering a safer and potentially more effective alternative to traditional cationic liposomes. These results lay the groundwork for future in vivo validation and translational cancer research. © 2026 The Author(s) | en_US |
| dc.description.sponsorship | This article is part of the doctoral research of Prof Nahide Zeren Arda Ozturk, conducted at Ege University, Turkiye. Prof Nahide Zeren Arda Ozturk received support from the TUBITAK 2214/A International Research Fellowship Programme (Project No. 1059B142201060) during her research stay at the University of Geneva, Switzerland. The financial and institutional support provided by the Ege University Office of Scientific Research Projects (Project No. 23840) and the TUBITAK 2244 Industrial PhD Fellowship Programme (Project No. 119C113) is gratefully acknowledged. Additional support from the Council of Higher Education through the 100/2000 scholarship programme is also sincerely appreciated. The authors extend their sincere gratitude to Abdi Ibrahim Pharmaceuticals for donating raw materials and serving as an industrial advisory partner within the TUBITAK 2244 programme.We also acknowledge Dr Claudia Simoes Avello and Mr Gael Vieille (University of Geneva) for assistance with the Qubit assay, Mrs Emmanuelle Sublet (University of Geneva) for support with cell culture, and Mr Tayeb Jbilou (University of Geneva) for assistance with TEM and SEM analyses. | |
| dc.description.sponsorship | This article is part of the doctoral research of Prof Nahide Zeren Arda Oztürk, conducted at Ege University , Turkiye. Prof Nahide Zeren Arda Oztürk received support from the TUBITAK 2214/A International Research Fellowship Programme (Project No. 1059B142201060 ) during her research stay at the University of Geneva , Switzerland. The financial and institutional support provided by the Ege University Office of Scientific Research Projects (Project No. 23840) and the TUBITAK 2244 Industrial PhD Fellowship Programme (Project No. 119C113 ) is gratefully acknowledged. Additional support from the Council of Higher Education through the 100/2000 scholarship programme is also sincerely appreciated. The authors extend their sincere gratitude to Abdi Ibrahim Pharmaceuticals for donating raw materials and serving as an industrial advisory partner within the TUBITAK 2244 programme. | |
| dc.description.sponsorship | Yükseköğretim Kurulu; Université de Genève, UNIGE; A International Research, (1059B142201060); Ege Üniversitesi, (23840); Ege Üniversitesi; Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, TUBITAK, (119C113); Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, TUBITAK | |
| dc.description.sponsorship | TUBITAK 2214/A International Research Fellowship Programme [1059B142201060]; Ege University Office of Scientific Research Projects [23840]; TUBITAK 2244 Industrial PhD Fellowship Programme [119C113]; Council of Higher Education through the 100/2000 scholarship programme | |
| dc.identifier.doi | 10.1016/j.ijpharm.2026.126715 | |
| dc.identifier.issn | 0378-5173 | |
| dc.identifier.issn | 1873-3476 | |
| dc.identifier.scopus | 2-s2.0-105031584374 | |
| dc.identifier.uri | https://doi.org/10.1016/j.ijpharm.2026.126715 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14627/1461 | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier B.V. | en_US |
| dc.relation.ispartof | International Journal of Pharmaceutics | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | (-)-Epigallocatechin-3-Gallate (EGCG) | en_US |
| dc.subject | Fully Synthetic Exosome-Mimetics (FSEMs) | en_US |
| dc.subject | Microfluidics | en_US |
| dc.subject | Microrna-23A (miR-23A) | en_US |
| dc.subject | Nanotechnology | en_US |
| dc.subject | Vesicular Drug Delivery Systems | en_US |
| dc.subject | (–)-Epigallocatechin-3-Gallate (EGCG) | |
| dc.title | Fully Synthetic, Nature-Inspired Exosome-Mimetics for Melanoma Therapy | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | Arda Ozturk, Nahide Zeren/0000-0001-9440-4230 | |
| gdc.author.scopusid | 59457870900 | |
| gdc.author.scopusid | 37029774600 | |
| gdc.author.scopusid | 60430197500 | |
| gdc.author.scopusid | 57222366085 | |
| gdc.author.scopusid | 7004023476 | |
| gdc.author.scopusid | 55601807000 | |
| gdc.author.scopusid | 55601807000 | |
| gdc.author.scopusid | 7003918121 | |
| gdc.author.wosid | Patrulea, Viorica/P-4334-2019 | |
| gdc.author.wosid | Arda, Zeren/KYQ-9206-2024 | |
| gdc.author.wosid | Ballar Kirmizibayrak, Petek/Y-6869-2018 | |
| gdc.author.wosid | ÖZER, Kevser/KBA-5695-2024 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.description.department | Fenerbahçe University | en_US |
| gdc.description.departmenttemp | [Arda Ozturk N.Z.] Fenerbahce University, Faculty of Pharmacy, Pharmaceutical Technology Department, Istanbul, Turkey, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, School of Pharmaceutical Sciences, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, Ege University, Faculty of Pharmacy, Pharmaceutical Technology Department, Izmir, Turkey; [Majchrzak O.B.] Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, School of Pharmaceutical Sciences, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland; [Ulivi G.] Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, School of Pharmaceutical Sciences, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland; [Kirmizibayrak P.B.] Ege University, Faculty of Pharmacy, Biochemistry Department, Izmir, Turkey; [Borchard G.] Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, School of Pharmaceutical Sciences, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland; [Patrulea V.] Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, School of Pharmaceutical Sciences, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland; [Ozer O.] Ege University, Faculty of Pharmacy, Pharmaceutical Technology Department, Izmir, Turkey | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | N/A | |
| gdc.description.volume | 693 | en_US |
| gdc.description.woscitationindex | Science Citation Index Expanded | |
| gdc.description.wosquality | Q1 | |
| gdc.identifier.openalex | W7131345978 | |
| gdc.identifier.pmid | 41759643 | |
| gdc.identifier.wos | WOS:001709051000001 | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.index.type | WoS | |
| gdc.openalex.fwci | 0.0 | |
| gdc.openalex.normalizedpercentile | 0.73 | |
| gdc.plumx.scopuscites | 0 | |
| gdc.scopus.citedcount | 0 |
